<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002014</url>
  </required_header>
  <id_info>
    <org_study_id>052A</org_study_id>
    <secondary_id>01</secondary_id>
    <nct_id>NCT00002014</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)</brief_title>
  <official_title>A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of various combinations of zidovudine (AZT) and&#xD;
      didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent&#xD;
      AZT and ddI administered orally. To evaluate the antiviral, immunologic and virologic effects&#xD;
      of AZT and ddI administered concurrently.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Acyclovir not to exceed two 14-day courses of therapy during trial. Discontinue ddI&#xD;
             while receiving acyclovir.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Positive HIV antibody using federally licensed ELISA test kit.&#xD;
&#xD;
          -  CD4 counts &lt; 400 on two consecutive visits within one month prior to entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT) if treated for less than 120 days.&#xD;
&#xD;
          -  Pharmacologic doses of steroids if given for management of Pneumocystis carinii&#xD;
             pneumonia (PCP) (not to exceed 21 days).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
        - Visceral or progressive Kaposi's sarcoma (KS) (defined by &gt; 10 new lesions in the thirty&#xD;
        days prior to entry) or patients who require chemotherapy or radiation therapy for Kaposi's&#xD;
        sarcoma. Other concurrent neoplasms other than basal cell carcinoma of skin or in situ&#xD;
        carcinoma of the cervix. Malabsorption as defined by persistent diarrhea ( &gt; 4 stools/day&#xD;
        for four weeks) which is unresponsive to antidiarrheal agents. Opportunistic infection&#xD;
        requiring maintenance therapy. History of Central Nervous System opportunistic infections&#xD;
        (e.g., toxoplasmosis, cryptococcosis). History of seizure disorders. Prior history of&#xD;
        pancreatitis. History of peripheral neuropathy or any significant signs or symptoms of&#xD;
        neurological disease. Examinations for peripheral neuropathy should assess changes in&#xD;
        extremities. Clinically significant hyperuricemia (tophaceous gout, urate nephropathy).&#xD;
        History of cardiomyopathy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Intravenous pentamidine.&#xD;
&#xD;
          -  Intravenous trimethoprim / sulfamethoxazole.&#xD;
&#xD;
          -  Alcohol.&#xD;
&#xD;
          -  Suppressive acyclovir therapy (see Inclusion Medications).&#xD;
&#xD;
          -  Allopurinol.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
          -  Isoniazid (INH).&#xD;
&#xD;
          -  Dipyridamole.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy for Kaposi's sarcoma.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) intolerance as evidenced by inability to tolerate at least 600 mg AZT&#xD;
             daily.&#xD;
&#xD;
          -  Previously intolerant to didanosine (ddI) evidenced by peripheral neuropathy or&#xD;
             seizures or pancreatitis or gastrointestinal toxicity or hematologic toxicity.&#xD;
&#xD;
          -  Diseases or conditions listed under Patient Exclusion Co-existing Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) for &gt; 120 days.&#xD;
&#xD;
          -  Dideoxycytidine (ddC).&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biological response modifiers.&#xD;
&#xD;
          -  Cytotoxic chemotherapy for Kaposi's sarcoma.&#xD;
&#xD;
          -  Excluded within 60 days of study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Transfusions.&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Radiation therapy for Kaposi's sarcoma.&#xD;
&#xD;
        Active substance abuse that would impair compliance with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981224304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

